CRISPR Therapeutics AG (CRSP) financial statements (2022 and earlier)

Company profile

Business Address BAARERSTRASSE 14
ZUG, CH-6300
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,3791,690944457240316
Cash and cash equivalents9231,169944457240316
Short-term investments1,456522    
Receivables000034
Other undisclosed current assets3826441051
Total current assets:2,4181,717988466248320
Noncurrent Assets
Operating lease, right-of-use asset1745142
Property, plant and equipment1384231191921
Intangible assets, net (including goodwill)000000
Intangible assets, net (excluding goodwill)000000
Restricted cash and investments17175333
Other noncurrent assets511110
Total noncurrent assets:33411179232325
TOTAL ASSETS:2,7521,8281,067489271345
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1077337261321
Accounts payable1596525
Accrued liabilities915430211116
Taxes payable1101000
Deferred revenue121
Debt  8   
Deferred rent credit   1
Deferred revenue and credits11
Other liabilities0711000
Other undisclosed current liabilities1211    
Total current liabilities:1209457281522
Noncurrent Liabilities
Long-term debt and lease obligation2135044   
Operating lease, liability2135044
Liabilities, other than long-term debt201926696990
Deferred revenue and credits6990
Deferred revenue121212
Contract with customer, liability58
Deferred rent credit   11
Other liabilities7814000
Total noncurrent liabilities:2336970696990
Total liabilities:3521641279784112
Stockholders' equity
Stockholders' equity attributable to parent2,3991,664939392188233
Common stock222211
Treasury stock, value(0)(0)(0)(0)  
Additional paid in capital2,5982,2361,162682312289
Accumulated other comprehensive income (loss)(5)(0)0(0)0(0)
Accumulated deficit(196)(574)(225)(292)(125)(57)
Total stockholders' equity:2,3991,664939392188233
TOTAL LIABILITIES AND EQUITY:2,7521,8281,067489271345

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues91512903415
Revenue, net51
Sublease income511
Revenue from related parties  13
Gross profit:91512903415
Operating expenses(541)(355)(243)(162)(106)(73)
Operating income (loss):374(354)47(159)(65)(68)
Nonoperating income (expense)6621(5)(2)45
Other nonoperating income (expense)6626(1)(0)79
Interest and debt expense     11
Income (loss) from continuing operations before equity method investments, income taxes:380(348)67(164)(67)(11)
Loss from equity method investments  (5)(4)(2)(37)
Other undisclosed income from continuing operations before income taxes  54225
Income (loss) from continuing operations before income taxes:380(348)67(164)(67)(23)
Income tax expense(2)(1)(0)(1)(2)(0)
Net income (loss):378(349)67(165)(68)(23)
Net income attributable to noncontrolling interest     0
Net income (loss) available to common stockholders, diluted:378(349)67(165)(68)(23)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss):378(349)67(165)(68)(23)
Other comprehensive income (loss)   (0)0 
Comprehensive income (loss):378(349)67(165)(68)(23)
Comprehensive income, net of tax, attributable to noncontrolling interest     0
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(5)(0)0  (0)
Comprehensive income (loss), net of tax, attributable to parent:373(349)67(165)(68)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: